Navigation Links
Tris Pharma Announces Appointment of Dr. Mahdi Fawzi as Top R&D Executive
Date:1/25/2012

MONMOUTH JUNCTION, N.J., Jan. 25, 2012 /PRNewswire/ -- Tris Pharma, an emerging specialty pharmaceutical company announced joining of a highly regarded Big Pharma executive Dr. Mahdi Fawzi to its leadership position as the Chief Scientific Officer and Executive Vice President of R&D including Regulatory Affairs.  

Throughout his career Dr. Fawzi has helped create a huge value as exemplified having many blockbuster drugs developed under his leadership such as Lipitor®, Enbrel®, Protonix®, Effexor XR®, Rapamune®, and Pristiq® among other.  Most recently Dr. Fawzi was President, Global Research & Development at Warner Chilcott where he led approval of Atelvia™ and Loestrin 24Fe, and managed integration of P&G's Pharmaceutical R&D operation. From 1995 to 2009, Dr. Fawzi was part of senior leadership team at Wyeth including last five years as Executive Vice President of Preclinical Development. Under his leadership Wyeth advanced 91 new molecules, filed 70 INDs, and 10 NDAs over last seven years prior to Pfizer merger. He oversaw 1300 scientists worldwide and managed a budget of over a quarter billion dollars. While at Wyeth, he won several prestigious industry awards and was one of the four finalists in 2004 for the Pharmaceutical Executive of the Year Award. He also held senior management positions at Warner Lambert and P&G. He is an author or co-author of over 50 publications and awarded more than 80 patents. He is a pharmacist by education and earned his M.S. and Ph.D. in Pharmaceutical Chemistry at University of Michigan.

"We are fortunate to have someone of Dr. Fawzi's caliber lead Tris R&D. Mahdi will lead our development, strengthen research base of various technology initiatives that are underway, direct clinical and regulatory disciplines," said Ketan Mehta, Tris' President and CEO. "Dr. Yu-Hsing Tu, who has led R&D for last ten years will focus on product development and report to Mahdi." 

"I am truly excited to be part of Tris' pioneering work involving new technologies, especially OralXR+ platform and its application in liquid and other unique dosage forms," stated Dr. Mahdi Fawzi. "Tris has accomplished a great deal in its relatively short history and I look forward to building upon the successes Dr. Tu and the R&D team has had to date."

About Tris Pharma

Tris Pharma is an emerging specialty pharmaceutical company focused on the research and development of drug delivery technologies based products. Through its OralXR+ platform, Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' Nobuse™ platform provides abuse-deterrence for opioids and other abuse-prone drugs. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey, USA. For more information, please visit www.trispharma.com.


'/>"/>
SOURCE Tris Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... 25, 2016 Inivata, a ... of circulating tumour DNA (ctDNA) analysis to improve ... of Professor Clive Morris as Chief ... the clinical development programme, scientific collaborations, and through ... significant improvements in clinical outcomes for patients. ...
(Date:5/24/2016)... May 24, 2016   , ... non-inferiority in overall bowel cleansing and superiority in ... leansing of the ... ) , Norgine B.V. today announced new positive data ... and ascorbate bowel preparation) versus standard 2 litre PEG with ascorbate. ...
(Date:5/24/2016)... INDIANAPOLIS , May 24, 2016  Joe Marziani has joined VMS BioMarketing as ... chief executive officer, today. In his new role, Marziani will lead the company,s business ... care professionals to improve outcomes. Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... ... Despite last week’s media reports hinting at a June rate hike after the Federal ... an interest rate increase, according to Rajeev Dhawan of the Economic Forecasting Center at ... Committee (FOMC) dot charts are of interest to the press for their noise potential,” ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, Pfizer, and 3M ... to court documents and SEC filings. A jury has returned a verdict ... Optical Corporation, Case No. BC588866, Los Angeles County, California. The jury awarded $22.8 ...
(Date:5/26/2016)... ... May 26, 2016 , ... Connor Sports, through its Connor Cares ... the Tamika Catchings Legacy Tour that will commemorate the Indiana Fever legend’s ... surfaces in all forms and levels of the game, Connor Sports has committed to ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cardiac arrhythmia is ... impact on long-term patient survival, reports a team of UPMC researchers in the ... in the Journal of Thoracic and Cardiovascular Surgery, provide critical information that will ...
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent ... for drugs, biologics, consumer health and global clinical supply services, today announced two ... support the company’s continued investment and strategic growth plans in the Asia Pacific ...
Breaking Medicine News(10 mins):